Abstract:

Neisseria meningitidis confronts us in a wide spectrum of diseases ranging from asymptomatic carriership to life-threatening invasive meningococcal disease. Worldwide, two types of meningococcal vaccines polysaccharide and conjugated are in clinical use against the disease. Polysaccharide meningococcal vaccines are preferred in countries where there is no access of conjugate vaccine in adolescents and young adults after the age of 2, who are particularly at risk for invasive meningococcal disease. As one of the conjugated meningococcal vaccines MenACWY-CRM is important since it can be used from 2 months of age. The results of the studies have shown that the MenACWY-CRM vaccine is effective and has a low side-effect profile in infants, children, adolescents and adults.

Keywords: